Serialization, or track and trace legislation, has been introduced to the pharmaceutical industry due to global concerns over patient safety and the number of counterfeit drugs currently in the market. However, these are not the only benefits to adopting serialization, and many companies should begin to look past compliance and on to the next stage.

Dexter Tjoa, Director Corporate Strategy, authored an article for World Pharma Today discussing the natural progression from serialization to aggregation in the pharmaceutical supply chain and how adopting aggregation now can bring benefits to your operations.

You can read the article in full here.